Acurion, Inc.
Acurion's OncoGaze™ technology delivers critical genomic insights at the biopsy stage, empowering oncologists to make precision therapy a reality for more patients.
Funding history
About Acurion, Inc.
How much funding has Acurion, Inc. raised?
Acurion, Inc. has raised $4.1M in total funding. The most recent round was Seed.
Where is Acurion, Inc. headquartered?
Acurion, Inc. is headquartered in San Diego, CA.
What does Acurion, Inc. do?
Acurion's OncoGaze™ technology delivers critical genomic insights at the biopsy stage, empowering oncologists to make precision therapy a reality for more patients.
What problem does Acurion, Inc. solve?
Despite nearly 100 FDA-approved precision oncology therapies, fewer than 1 in 20 cancer patients actually receive them.
What's Acurion, Inc.'s solution?
Acurion's OncoGaze delivers genomic biomarker insights at the biopsy stage, predicting clinically actionable biomarkers from routine digital histological tissue slides to help oncologists apply precision therapy more broadly.
What makes Acurion, Inc. different?
It claims to uncover morphological patterns invisible to the human eye and return actionable genomic results within seconds rather than months, with technology developed by highly cited cancer researchers.
What makes Acurion, Inc. notable?
Co-founded by Ludmil B. Alexandrov, PhD, a UC San Diego professor known for his cancer genomics research, who serves as the company's Chief Scientific Officer; Acurion has raised $4.3M for cancer diagnostics.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.